Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy

AK Dubey, E Mostafavi - Frontiers in Chemistry, 2023 - frontiersin.org
The use of biomaterials in delivering CRISPR/Cas9 for gene therapy in infectious diseases
holds tremendous potential. This innovative approach combines the advantages of …

The chemokine receptor CCR5: multi-faceted hook for HIV-1

N Faivre, C Verollet, F Dumas - Retrovirology, 2024 - Springer
Chemokines are cytokines whose primary role is cellular activation and stimulation of
leukocyte migration. They perform their various functions by interacting with G protein …

[HTML][HTML] CRISPR-Cas12b enables a highly efficient attack on HIV proviral DNA in T cell cultures

M Fan, Y Bao, B Berkhout, E Herrera-Carrillo - Biomedicine & …, 2023 - Elsevier
Abstract Background The novel endonuclease Cas12b was engineered for targeted
genome editing in mammalian cells and is a promising tool for certain applications because …

[HTML][HTML] HIV-1 proviral DNA in purified peripheral blood CD34+ stem and progenitor cells in individuals with long-term HAART; paving the way to HIV gene therapy

B Tassaneetrithep, A Phuphuakrat, E Pasomsub… - Heliyon, 2024 - cell.com
Abstract Human immunodeficiency virus (HIV)-1 infection is an important public health
problem worldwide. After primary HIV-1 infection, transcribed HIV-1 DNA is integrated into …

JAK/STAT signaling pathway affects CCR5 expression in human CD4+ T cells

L Wang, Y Yukselten, J Nuwagaba, RE Sutton - Science Advances, 2024 - science.org
CCR5 serves as R5-tropic HIV co-receptor. Knocking out CCR5 in HIV patients, which has
occurred< 10 times, is believed important for cure. JAK/STAT inhibitors tofacitinib and …

CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1

W Khamaikawin, C Saisawang, B Tassaneetrithep… - Scientific Reports, 2024 - nature.com
Hematopoietic stem-cell (HSC) transplantation using a donor with a homozygous mutation
in the HIV co-receptor CCR5 (CCR5Δ32/Δ32) holds great promise as a cure for HIV-1 …

A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5-and CXCR4-tropic HIV-1 infection

AM Dudek, WN Feist, EJ Sasu, SE Luna, K Ben-Efraim… - Cell stem cell, 2024 - cell.com
Allogeneic hematopoietic stem and progenitor cell transplant (HSCT) of CCR5 null
(CCR5Δ32) cells can be curative for HIV-1-infected patients. However, because allogeneic …

[HTML][HTML] Plasma, Intracellular and Lymph Node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 …

A De Nicolò, A Palermiti, S Dispinseri… - International Journal of …, 2024 - Elsevier
Despite its effectiveness, combination antiretroviral treatment (cART) has a limited effect on
HIV DNA reservoir, which establishes early during primary HIV infection (PHI) and is …

[PDF][PDF] The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.

M Saifullah, O Laghzaoui… - European Review for …, 2024 - europeanreview.org
Human Immunodeficiency Virus (HIV) has continuously been the greatest epidemic for
humanity over a period spanning almost five decades. With no specific cure or treatment …

Killing two birds with one stone: CRISPR/Cas9 CCR5 knockout hematopoietic stem cells transplantation to treat patients with HIV infection and hematological …

TY Au, J Arudkumar, C Assavarittirong… - Clinical and Experimental …, 2023 - Springer
Human immunodeficiency virus (HIV) is known to cause hematological malignancy.
Hematopoietic stem cell transplantation (HPSCT) is an advanced treatment for that …